KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrana Health (ASTH) Payables (2016 - 2025)

Astrana Health's Payables history spans 14 years, with the latest figure at $106.8 million for Q4 2024.

  • For Q4 2024, Payables rose 999.35% year-over-year to $106.8 million; the TTM value through Dec 2024 reached $106.8 million, up 999.35%, while the annual FY2024 figure was $106.8 million, 999.35% up from the prior year.
  • Payables for Q4 2024 was $106.8 million at Astrana Health, up from $95.4 million in the prior quarter.
  • Across five years, Payables topped out at $147.1 million in Q1 2024 and bottomed at $8.1 million in Q1 2020.
  • The 5-year median for Payables is $37.7 million (2020), against an average of $42.1 million.
  • The largest annual shift saw Payables crashed 80.66% in 2023 before it surged 999.35% in 2024.
  • A 5-year view of Payables shows it stood at $36.6 million in 2020, then increased by 21.51% to $44.5 million in 2021, then rose by 12.85% to $50.2 million in 2022, then plummeted by 80.66% to $9.7 million in 2023, then soared by 999.35% to $106.8 million in 2024.
  • Per Business Quant, the three most recent readings for ASTH's Payables are $106.8 million (Q4 2024), $95.4 million (Q3 2024), and $38.9 million (Q2 2024).